29/03/2019 19:00:00

AVP, BRS & TAP - Bronstein, Gewirtz & Grossman, LLC Class Action Update

NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Avon Products, Inc. (NYSE: AVP)

Class Period: August 2, 2016 - August 2, 2017

Deadline: April 15, 2019

For more info:www.bgandg.com/avp

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Avon was engaged in an undisclosed scheme whereby it significantly loosened its credit terms in order to recruit new representatives in Brazil, its largest market; (2) its specific credit terms in Brazil; (3) Avon failed to increase its allowance for doubtful accounts to account for the changes to its credit terms in Brazil; and (4) as a result of these concealments, Avon stock was trading at artificially inflated prices throughout the class period.

Molson Coors Brewing Company

(NYSE: TAP)

Class Period: February 14, 2017 - February 11, 2019

Deadline: April 16, 2019

For more info:www.bgandg.com/tap

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Molson Coors failed to properly reconcile the outside basis deferred income tax liability for Molson Coors’ investment in its MillerCoors, LLC partnership; (2) consequently, Molson Coors misreported net income in its consolidated financial statements for the fiscal years ending December 31, 2016 and December 31, 2017, resulting in an overall downward revision to net income; (3) Molson Coors lacked adequate internal controls over financial reporting; and (4) as a result, defendants’ statements about Molson Coors’ business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Bristow Group Inc. (NYSE: BRS)

Class Period: February 8, 2018 - February 12, 2019

Deadline: April 15, 2019

For more info:www.bgandg.com/brs

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Bristow lacked adequate monitoring processes related to non-financial covenants within its secured financing and lease agreements; (2) Bristow could not reasonably assure compliance with certain non-financial covenants; (3) Bristow was reasonably likely to breach certain agreements; (4) Bristow had understated its short-term debt; (5) the required corrections would materially impact financial statements; (6) there was a material weakness in Bristow’s internal controls over financial reporting; and (7) as a result of the foregoing, defendants’ positive statements about Bristow's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

BGG Logo.jpg

Related content
15 Aug - 
Shareholder Investigation Alert: Halper Sadeh LLP is In..
15 Aug - 
Bragar Eagel & Squire is Investigating Certain Officers..
13 Aug - 
Molson Investigated by Merchant Law Group LLP For Viola..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock
2
MYGN Loss Alert: Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations
3
Bone Therapeutics SA to report half year 2019 results on 30 August 2019
4
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
5
Ambu A/S: Interim report for Q3 2018/19

Related stock quotes

Molson Coors Brewing Com.. 51.78 -0.7% Stock price decreasing
Avon Products Inc 4.110 0.7% Stock price increasing

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 August 2019 11:09:30
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB3 - 2019-08-22 12:09:30 - 2019-08-22 11:09:30 - 1000 - Website: OKAY